Lipid Nanoparticle-mRNA Vaccines Against Chlamydia psittaci: Insights from Preclinical Evaluation

Study Background and Research Question

Chlamydia psittaci is a zoonotic pathogen primarily affecting birds but capable of causing severe respiratory disease in humans and livestock. Human infection, known as psittacosis, presents with a spectrum of symptoms from pneumonia to extrapulmonary complications such as myocarditis and neurological disorders. The increasing incidence of C. psittaci, combined with frequent asymptomatic cases and risk of recrudescence following empirical antibiotic use, underscores the urgent need for effective vaccines (Wang et al., 2025). However, traditional vaccine platforms face challenges in eliciting robust immunity against intracellular bacteria with complex life cycles. The emergence of mRNA vaccines offers a promising alternative, leveraging rapid design cycles and the potential for immune response tailoring via nucleotide modifications.

Key Innovation from the Reference Study

The central innovation reported by Wang et al. is the development and preclinical evaluation of a lipid nanoparticle (LNP)-delivered mRNA vaccine encoding the major outer membrane protein (MOMP) of C. psittaci. This approach integrates recent advances in non-replicating, chemically modified mRNA design—specifically incorporating nucleoside modifications such as pseudouridine to enhance protein expression and reduce innate immune sensing. Encapsulation in LNPs addresses delivery hurdles, promoting mRNA uptake and translation in host cells. The study stands out by demonstrating not only successful mRNA vaccine construction, but also its protective efficacy and immunogenicity in a mouse model of chlamydial infection (Wang et al., 2025).

Methods and Experimental Design Insights

The researchers constructed a non-replicating, codon-optimized mRNA encoding the MOMP antigen, synthesized via an in vitro transcription system. The mRNA incorporated chemical modifications to maximize translation and minimize immune activation, aligning with established benefits of pseudouridine and N-1-methylpseudouridine in mRNA vaccines. The resulting mRNA was encapsulated in LNPs, which were then characterized for particle size, morphology, and cytotoxicity prior to in vivo use.

In vitro validation involved transfecting HeLa cells with the mRNA-LNPs and confirming MOMP expression via western blotting. For in vivo assessment, BALB/c mice were immunized with the LNP-mRNA vaccine and subsequently challenged with C. psittaci. Disease outcomes were evaluated through lung histopathology, chlamydial load quantification, and measurement of key cytokines (interferon-γ, TNF-α, IL-6) in lung tissue. Indirect immunofluorescence was used to monitor pathogen shedding, providing a functional readout of vaccine efficacy.

Protocol Parameters

• Antigen design: Codon-optimized MOMP sequence for enhanced mammalian translation.
• mRNA synthesis: In vitro transcription with modified nucleotides (e.g., pseudouridine) to support immune response reduction by modified nucleotides.
• LNP formulation: Particle size and composition optimized for efficient mRNA delivery and minimal cytotoxicity.
• Immunization regimen: Dosing and timing tailored to achieve measurable immune responses and protection prior to pathogen challenge.
• Outcome measures: Pathogen load, cytokine profiling, histopathology, and antigen-specific immune readouts post-challenge.

These parameters mirror current best practice in RNA vaccine development and in vitro translation of modified mRNA, with a focus on balancing immunogenicity and safety.

Core Findings and Why They Matter

The LNP-mRNA vaccine encoding C. psittaci MOMP yielded several important outcomes (Wang et al., 2025):

• Robust antigen expression: In vitro assays confirmed efficient translation of the MOMP antigen following mRNA transfection.
• Protective immunity: Immunized mice exhibited marked reductions in lung chlamydial load and pathogen shedding compared to controls.
• Effective immune modulation: Vaccinated animals showed lower levels of pro-inflammatory cytokines (IFN-γ, TNF-α, IL-6) in lung tissue, suggesting reduced tissue damage and better infection control.
• Histopathological evidence: Lung sections from vaccinated mice displayed less inflammation and damage post-challenge.

Together, these findings provide strong preclinical support for mRNA vaccine platforms against respiratory pathogens. Of note, the study underscores the impact of nucleotide modifications—such as pseudouridine—on both mRNA stability and immune profile, a theme echoed in related works on immune response reduction by modified nucleotides.

Comparison with Existing Internal Articles

The workflow and results described in Wang et al. align closely with scenario-driven approaches detailed in recent internal literature. For instance, the scenario-driven analysis of the HyperScribe All in One mRNA Synthesis Kit Plus 1 highlights how integrated synthesis and modification steps streamline the generation of ARCA-capped, polyadenylated, and immune-evasive mRNA for vaccine development, RNA interference (RNAi) experiments, and in vitro translation. Similarly, the workflow and application overview demonstrates how the co-transcriptional introduction of 5mCTP and ψUTP reduces innate immune sensing, paralleling the reference study’s use of modified nucleotides to optimize mRNA function in vivo.

These internal resources reinforce the translational value of robust, one-pot mRNA synthesis protocols, which are essential for reproducible research on mRNA vaccines against pathogens such as C. psittaci. The adoption of ARCA-capped mRNA synthesis kits with built-in poly(A) tailing and nucleotide modification capabilities not only accelerates project timelines but also enhances experimental reliability and downstream immunogenicity outcomes.

Limitations and Transferability

While the results of Wang et al. are compelling, some limitations should be considered. The study was conducted in mice, and while BALB/c models are informative for respiratory infection and immunity, species-specific differences may affect the translation of vaccine efficacy to humans. The immunization regimen and dosing require optimization for larger-scale or clinical settings. Moreover, the study focuses on a single antigen (MOMP), and it remains to be seen whether multi-antigen or combination approaches could further improve protection against diverse C. psittaci strains or related Chlamydia species.

Transferability of the workflow is high for other respiratory or intracellular pathogens, provided that antigen selection and mRNA design principles are maintained. The modularity of in vitro transcription, LNP formulation, and nucleotide modification lends itself to rapid adaptation for new targets, a feature now well-established in the field of RNA vaccine development.

Why this cross-domain matters, maturity, and limitations

The cross-domain application—from mRNA vaccine technologies developed for viral pathogens to bacterial zoonoses such as C. psittaci—demonstrates the versatility of the platform. The principles of mRNA stability, translation efficiency, and immune modulation are broadly applicable, yet pathogen-specific challenges (antigen structure, host-pathogen interactions) must be addressed in each context. The technology’s maturity is reflected in rapid preclinical progress and growing translational pipelines, but further validation in humans and across diverse pathogens is still needed.

Research Support Resources

For researchers aiming to replicate or extend such workflows, the HyperScribe™ All in One mRNA Synthesis Kit Plus 1 (ARCA, 5mCTP, ψUTP, T7, poly(A)) (SKU K1064) from APExBIO provides a comprehensive solution for ARCA-capped, polyadenylated, and chemically modified mRNA synthesis. This kit enables efficient co-transcriptional capping and incorporation of 5mCTP and ψUTP, supporting high-yield, immune-evasive mRNA suitable for in vitro translation, RNAi, and vaccine prototyping. For further workflow insights and comparative guidance, internal articles such as the mechanistic overview are available to support experimental design decisions.